On July 29, 2021 KG Legal Kiełtyka Gładkowski will take part in webinar ‘Cell and gene data innovation and multi-stakeholder data transfer’ organized by Reuters as part of the activities of Pharma Boardroom (the global platform for C -level healthcare executives) in partnership with Sales force. This online-conference will focus on the life-changing cell and gene therapies and related with it value chains of these therapies and data transfer between the stakeholders.
The main topic of the webinar and the core issues discussed are crucial from the perspective of KIELTYKA GLADKOWSKI expertise, especially within pharma, life sciences & healthcare cases, as well as health tech and digital health.
The core of the webinar is concentrated on the problem of the flow and exchange of data. As the organizers announced and emphasized ‘the problem of these complex and delicate value chains (problem of data flow) is something pharma has traditionally never seen before’. This is because nowadays medicine therapies and especially data and gene therapies in particular are remarkably complex- from developing of the therapy to the regulators’ approval and the marketing of a medical product. The panelists will include:
Mr. Augusto Penjasoff is an Business and IT Leader within Life Sciences and Consulting. He as extensive experience in leadership, business organization and strategic insight. He is currently leading Digital Innovation at Mallinckrodt Pharmaceuticals. In that project he is responsible for establishing and implementing a strategy of delivering new levels of technology innovation and business transformation through technology to the enterprise (with the goal to place Patients at the center). Mr. Penjasoff is also a regional and global Leader at Merc and Schering- Plough.
Mr. Curt Fitzgerald is a Director in the Novartis. He is a global transformation leader delivering performance outcomes via digital enablement, artificial intelligence, change management, operations management, compliance adherence, and business application development. He specializes in business process engineering, digitalization, software development, customer/ patient- centric service, knowledge management.
Mr. Gary Gabriel is a Ph. D. in a biochemistry and Molecular Biology. He has provided Healthcare and Life Science expertise and business leadership. He is collaborating with executives within healthcare and life science to apply descriptive and predictive analytics to personalized medicine and real world evidence initiatives in life science, pharma, medical device. Dr. Gabriel is supporting and creating life science partnerships to build a range of scalable analytics initiatives in pre and post market cell and gene therapy, targeted therapy, and immuno-oncology.
Ms. Neary Detrick is a Senior Director, Enterprise Data Management & Analytics at bluebird bio. All in all bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company’s gene therapy procedures aim to genetically modify a patient’s cells to fundamentally correct or address the genetic basis underlying a disease.
Beth Hayes is a business leader in strategy
development, digital transformation, global implementations, process and
organization design. She has broad industry and consulting experience
especially on solving complex business challenges.
 https://hmgstrategy.com/network/people/augusto-penjasoff, (access date: 27th July,2021)
 https://www.linkedin.com/in/curt-fitzgerald-83123a1/, (access date: 27th July,2021)
 https://www.linkedin.com/in/gary-gabriel-ph-d-bba87213b/, (access date: 27th July,2021)
 https://www.linkedin.com/in/neary-detrick-393b1466/; https://www.apollo.io/people/Neary/Detrick/55708eb973696421d1a50200, (access date: 27th July,2021)